VRDN Stock Price, Viridian Therapeutics, . Quote, Chart

Market Summary

USD13.42-1.21

Delayed

-8.27%

VRDN Stock Price

View Fullscreen

VRDN RSI Chart

VRDN Valuation

Market Cap

856.5M

Price/Earnings (Trailing)

-3.93

Price/Sales (Trailing)

156.37

Price/Free Cashflow

-5.09

VRDN Price/Sales (Trailing)

VRDN Profitability

Operating Margin

58.07%

Return on Equity

-37.44%

Return on Assets

-34.6%

Free Cashflow Yield

-19.64%

VRDN Fundamentals

VRDN Revenue

Revenue (TTM)

6.1M

Rev. Growth (Yr)

298.85%

Rev. Growth (Qtr)

-3.73%

VRDN Earnings

Earnings (TTM)

-218.1M

Earnings Growth (Yr)

28.77%

Earnings Growth (Qtr)

27.4%

Breaking Down VRDN Revenue

Last 7 days

-3.4%

Last 30 days

-11.0%

Last 90 days

-27.8%

Trailing 12 Months

-40.5%

How does VRDN drawdown profile look like?

VRDN Financial Health

Current Ratio

23.99

Debt/Equity

0.03

Debt/Cashflow

-8.24

VRDN Investor Care

Shares Dilution (1Y)

47.97%

Diluted EPS (TTM)

-4.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	6.1M	0	0	0
2022	1.7M	874.0K	1.7M	1.8M
2021	1.7M	2.6M	2.8M	3.0M
2020	4.9M	2.6M	1.9M	1.1M
2019	4.0M	4.3M	4.1M	4.5M
2018	8.3M	9.8M	9.1M	8.4M
2017	3.0M	2.6M	3.3M	4.0M
2016	2.8M	3.2M	3.6M	3.5M
2015	3.9M	3.4M	3.0M	2.5M
2014	4.3M	4.8M	5.7M	4.3M
2013	0	4.4M	4.3M	4.3M
2012	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Viridian Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 28, 2024	fairmount funds management llc	sold	-	-	-5,859	-
Mar 28, 2024	fairmount funds management llc	acquired	-	-	5,859	-
Jan 22, 2024	fairmount funds management llc	bought	9,999,990	21.00	476,190	-
Jun 16, 2023	meisner lara	acquired	621	23.03	27.00	chief legal officer
Jun 16, 2023	meisner lara	sold	-765	28.35	-27.00	chief legal officer
Jun 15, 2023	meisner lara	sold	-63,577	28.02	-2,269	chief legal officer
Jun 15, 2023	meisner lara	acquired	52,255	23.03	2,269	chief legal officer
Jun 06, 2023	meisner lara	acquired	94,882	18.51	5,126	chief legal officer
Jun 06, 2023	meisner lara	sold	-128,253	25.02	-5,126	chief legal officer
Jun 05, 2023	meisner lara	sold	-12,490	25.03	-499	chief legal officer

Which funds bought or sold VRDN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	13.91	-68,585	745,856	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-26.9	-610,411	869,932	-%
May 16, 2024	COMERICA BANK	unchanged	-	-255	1,047	-%
May 15, 2024	Woodline Partners LP	new	-	7,685,520	7,685,520	0.07%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-8.33	-1,024,990	2,871,870	0.02%
May 15, 2024	Squarepoint Ops LLC	new	-	472,000	472,000	-%
May 15, 2024	VR Adviser, LLC	added	-	-16,578,000	67,985,600	3.23%
May 15, 2024	Eversept Partners, LP	added	3.45	-503,598	2,487,730	0.17%
May 15, 2024	MPM BIOIMPACT LLC	added	514	8,573,320	10,751,300	1.73%
May 15, 2024	Walleye Capital LLC	reduced	-97.67	-5,159,250	98,686	-%

Are Funds Buying or Selling VRDN?

Are funds buying VRDN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VRDN

No. of Funds

Unveiling Viridian Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	fairmount funds management llc	18.64%	13,956,685	SC 13D/A
Feb 14, 2024	commodore capital lp	3.7%	1,924,074	SC 13G/A
Feb 14, 2024	deep track capital, lp	9.90%	5,378,997	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.99%	5,555,568	SC 13G/A
Feb 14, 2024	paradigm biocapital advisors lp	9.99%	5,304,313	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.71%	3,000,948	SC 13G/A
Jan 29, 2024	blackrock inc.	6.5%	3,426,450	SC 13G/A
Jan 29, 2024	perceptive advisors llc	6.7%	4,022,066	SC 13G
Jan 24, 2024	state street corp	5.15%	2,708,383	SC 13G

Recent SEC filings of Viridian Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 16, 2024	8-K	Current Report
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	SC 13D/A	13D - Major Acquisition
Feb 28, 2024	S-8	Employee Benefits Plan
Feb 27, 2024	10-K	Annual Report

Peers (Alternatives to Viridian Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Viridian Therapeutics, Inc. News

Latest updates

Viridian Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	4,164	4,326	4,487	291	1,044	256	196	214	208	1,090	1,451	54.00	-	168	828	880	695	2,514	372
Operating Expenses	-21.8%	55,969	71,550	51,296	59,347	72,571	49,171	30,980	29,820	26,105	29,295	14,342	19,088	19,966	90,652	5,410	6,542	8,826	10,951	11,925	11,456	12,108
S&GA Expenses	-100.0%	-	32,993	20,911	19,264	21,831	9,854	8,861	8,108	8,359	6,901	6,221	6,523	6,160	5,537	2,299	2,706	2,723	2,534	2,898	2,857	3,357
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,111	3,836	6,103	8,417	9,027	8,599	8,751
Interest Expenses	0%	452	452	-	-	112	149	77.00	-	-	-	-	-	-	69.00	53.00	84.00	61.00	105	129	141	136
Net Income	27.4%	-48,542	-66,860	-47,660	-55,063	-68,151	-45,785	-28,905	-29,491	-25,693	-28,946	-14,043	-17,964	-18,460	-90,742	-5,494	-6,435	-8,044	-10,118	-11,230	-8,896	-11,629
Net Income Margin	8.2%	-35.89*	-39.12*	-35.65*	-32.56*	-28.36*	-72.70*	-66.10*	-112.33*	-50.73*	-26.80*	-50.38*	-51.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	-18.9%	-45,223	-38,048	-39,387	-45,545	-62,088	-34,273	-20,763	-18,378	-21,221	-16,619	-12,061	-14,685	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	28.5%	630	490	329	351	387	435	441	170	183	204	221	118	123	131	33.00	33.00	39.00	30.00	39.00	49.00	55.00
Current Assets	28.8%	627	486	324	346	383	431	437	166	179	200	218	115	122	130	32.00	33.00	38.00	30.00	38.00	48.00	54.00
Cash Equivalents	-10.9%	92.00	103	112	87.00	89.00	156	344	31.00	31.00	42.00	139	28.00	46.00	46.00	30.00	31.00	36.00	25.00	25.00	24.00	18.00
Net PPE	-8.7%	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00
Liabilities	-1.1%	48.00	48.00	45.00	36.00	36.00	40.00	32.00	28.00	17.00	16.00	17.00	19.00	17.00	11.00	12.00	12.00	12.00	15.00	16.00	15.00	14.00
Current Liabilities	-1.9%	26.00	27.00	23.00	29.00	30.00	33.00	25.00	21.00	14.00	14.00	14.00	17.00	16.00	11.00	8.00	7.00	9.00	10.00	10.00	9.00	7.00
Long Term Debt	0.6%	20.00	20.00	20.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	31.8%	583	442	284	316	351	395	409	142	167	188	205	99.00	106	120	21.00	21.00	27.00	16.00	23.00	33.00	41.00
Retained Earnings	-6.7%	-774	-725	-659	-611	-556	-488	-442	-413	-384	-358	-329	-315	-297	-278	-188	-182	-176	-168	-158	-146	-137
Additional Paid-In Capital	20.5%	1,157	961	807	792	772	741	710	453	439	412	372	260	242	218	209	203	203	184	181	180	179
Shares Outstanding	18.2%	64.00	54.00	44.00	44.00	43.00	41.00	29.00	28.00	26.00	12.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,021	-	-	-	329	-	-	-	157	-	-	-	59.00	-	-	-	57.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-19.0%	-45,223	-38,000	-38,983	-45,214	-61,973	-34,042	-20,668	-18,086	-21,042	-16,535	-11,876	-14,631	-11,539	-9,436	-5,095	-6,789	-8,459	-7,806	-9,267	-7,174	-11,809
Share Based Compensation	-51.3%	12,688	26,048	13,606	12,302	15,216	5,278	4,943	4,885	4,659	3,491	3,982	3,817	3,175	1,743	615	623	664	1,003	874	1,075	1,018
Cashflow From Investing	15.7%	-143,045	-169,711	48,041	40,713	-13,295	-180,603	42,651	13,963	8,863	-80,210	6,251	-11,205	10,872	-52,429	-53.00	-	2,001	7,000	11,021	13,025	-2,820
Cashflow From Financing	-11.0%	177,082	198,941	15,457	3,068	8,204	26,014	290,934	4,558	738	170	116,794	7,052	1,259	77,683	4,645	1,268	17,715	795	-904	-39.00	218

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VRDN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Collaboration revenue - related party	$ 72	$ 98
Operating expenses:
Research and development (including related party expenses of $661 and $3,244 during the three months ended March 31, 2024 and 2023, respectively.)	40,944	50,740
General and administrative	15,025	21,831
Total operating expenses	55,969	72,571
Loss from operations	(55,897)	(72,473)
Other income:
Interest and other income	7,942	4,487
Interest and other expense	(587)	(165)
Other income, net	7,355	4,322
Net loss	$ (48,542)	$ (68,151)
Net loss per share, basic (in dollars per share)	$ (0.79)	$ (1.61)
Net loss per share, diluted (in dollars per share)	$ (0.79)	$ (1.61)
Weighted-average shares used to compute basic net loss per share (in shares)	61,099,038	42,242,309
Weighted-average shares used to compute diluted net loss per share (in shares)	61,099,038	42,242,309
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Net loss	$ (48,542)	$ (68,151)
Other comprehensive (loss) gain:
Change in unrealized (loss) gain on investments	(705)	216
Total other comprehensive (loss) gain	(705)	216
Total comprehensive loss	$ (49,247)	$ (67,935)

VRDN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 91,641	$ 102,827
Short-term investments	521,546	374,543
Prepaid expenses and other current assets (including related party of $1,137 and $0 as of March 31, 2024 and December 31, 2023, respectively)	13,529	9,006
Unbilled revenue - related party	102	102
Total current assets	626,818	486,478
Property and equipment, net	1,526	1,672
Operating lease right-of-use asset	1,482	1,670
Other assets	555	604
Total assets	630,381	490,424
Current liabilities:
Accounts payable	2,676	2,239
Accrued liabilities and other (including related party of $637 and $374 as of March 31, 2024 and December 31, 2023, respectively)	23,163	24,108
Current portion of deferred revenue - related party	288	288
Total current liabilities	26,127	26,635
Long-term debt, net	20,328	20,205
Deferred revenue - related party	500	573
Other liabilities	896	989
Total liabilities	47,851	48,402
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 200,000,000 shares authorized; 63,798,536 and 53,986,112 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	638	540
Additional paid-in capital	1,156,999	960,536
Accumulated other comprehensive (loss) gain	(367)	338
Accumulated deficit	(774,450)	(725,908)
Total stockholders’ equity	582,530	442,022
Total liabilities and stockholders’ equity	630,381	490,424
Series A Preferred Stock
Stockholders’ equity:
Preferred stock	71,429	78,235
Series B Preferred Stock
Stockholders’ equity:
Preferred stock	$ 128,281	$ 128,281

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

CEO	Mr. Scott D. Myers M.B.A.
WEBSITE	viridiantherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	86

Viridian Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Viridian Therapeutics, Inc.? What does VRDN stand for in stocks?

VRDN is the stock ticker symbol of Viridian Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viridian Therapeutics, Inc. (VRDN)?

As of Fri May 17 2024, market cap of Viridian Therapeutics, Inc. is 856.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VRDN stock?

You can check VRDN's fair value in chart for subscribers.

What is the fair value of VRDN stock?

You can check VRDN's fair value in chart for subscribers. The fair value of Viridian Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viridian Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VRDN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viridian Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VRDN is over valued or under valued. Whether Viridian Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Viridian Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VRDN.

What is Viridian Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VRDN's PE ratio (Price to Earnings) is -3.93 and Price to Sales (PS) ratio is 156.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VRDN PE ratio will change depending on the future growth rate expectations of investors.